Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 32, 06 March 2024
Open
Access | Article
Unlocking the diagnostic potential: N-Glycan profiling for distinguishing breast cancer patients from healthy individuals
* Author to whom correspondence should be addressed.
Abstract
Chest sickness is now the most broadly perceived dangerous development, addressing 12.5% of all new yearly harmful development cases all over the planet. Around 13% (around 1 out of 8) of U.S. women will cultivate prominent chest illness all through their lives. In 2022, a normal 287,850 new occurrences of prominent chest illness should be examined in women in the U.S., close to 51,400 new examples of easy chest dangerous development. The exploration directed a review where N-glycans were gotten from the serum of bosom disease patients and solid people, and their general overflow contrasts were used for primer bosom malignant growth determination. Through Fractional Least Squares Discriminant Examination (PLS-DA), the creator had the option to successfully recognize bosom malignant growth patients from the sound populace, demonstrating the capability of N-glycan profiles in segregating between bosom disease and non-bosom disease people. This examination denotes a promising step towards the improvement of expected demonstrative and prognostic markers for bosom disease, giving likely biomarkers to beginning-phase bosom malignant growth patients. The discoveries of this study might hold critical pertinence in the field of bosom disease determination and treatment.” This exploration will utilize work area and trial. Past assessment found that the level of serum N-glycan A2G1(6)FB, a biantennary N-glycan containing focus fucose and bisecting GlcNAc developments was higher in chest-threatening development patients than in those without chest illness. Additionally, A2G1(6)FB was recognizable in chest dangerous development patients with starting stage and could be a precise marker. Hence, concurrent utilization of IgG blood tests and customary biomarkers could work on the exactness of bosom disease determination, recommending that IgG blood tests might be a solid biomarker for beginning phase bosom malignant growth patients.
Keywords
Breast cancer, biomarker, serum N-glycan
References
1. Siegel, R. L.; Miller, K. D.; Jemal, A., Cancer statistics, 2020. CA Cancer J Clin 2020, 70 (1), 7-30.
2. Potapenko, I. O.; Luders, T.; Russnes, H. G.; Helland, A.; Sorlie, T.; Kristensen, V. N.; Nord, S.; Lingjaerde, O. C.; Borresen-Dale, A. L.; Haakensen, V. D., Glycan-related gene expression signatures in breast cancer subtypes; relation to survival. Mol Oncol 2015, 9 (4), 861-76.
3. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R. L.; Torre, L. A.; Jemal, A., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, 68 (6), 394-424.
4. DeSantis, C. E.; Ma, J.; Goding Sauer, A.; Newman, L. A.; Jemal, A., Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 2017, 67 (6), 439-448.
5. Magers, M. J.; Lopez-Beltran, A.; Montironi, R.; Williamson, S. R.; Kaimakliotis, H. Z.; Cheng, L., Staging of bladder cancer. Histopathology 2019, 74 (1), 112-134.
6. Kotsopoulos, J.; Huzarski, T.; Gronwald, J.; Singer, C. F.; Moller, P.; Lynch, H. T.; Armel, S.; Karlan, B.; Foulkes, W. D.; Neuhausen, S. L.; Senter, L.; Tung, N.; Weitzel, J. N.; Eisen, A.; Metcalfe, K.; Eng, C.; Pal, T.; Evans, G.; Sun, P.; Lubinski, J.; Narod, S. A.; Hereditary Breast Cancer Clinical Study, G., Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst 2017, 109 (1).
7. Zhong, G.; Wang, K.; Li, J.; Xiao, S.; Wei, W.; Liu, J., Determination of Serum Exosomal H19 as a Noninvasive Biomarker for Breast Cancer Diagnosis. Onco Targets Ther 2020, 13, 2563-2571.
8. Li, M.; Zou, X.; Xia, T.; Wang, T.; Liu, P.; Zhou, X.; Wang, S.; Zhu, W., A five-miRNA panel in plasma was identified for breast cancer diagnosis. Cancer Med 2019, 8 (16), 7006-7017.
9. Scupakova, K.; Adelaja, O. T.; Balluff, B.; Ayyappan, V.; Tressler, C. M.; Jenkinson, N. M.; Claes, B. S.; Bowman, A. P.; Cimino-Mathews, A. M.; White, M. J.; Argani, P.; Heeren, R. M.; Glunde, K., Clinical importance of high-mannose, fucosylated, and complex N-glycans in breast cancer metastasis. JCI Insight 2021, 6 (24).
10. Yu, R.; Longo, J.; van Leeuwen, J. E.; Zhang, C.; Blanchard, E.; Elbaz, M.; Cescon, D. W.; Drake, R. R.; Dennis, J. W.; Penn, L. Z., Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced N-glycosylation Abundance and Branching. Cancer Res 2021, 81 (10), 2625-2635.
11. Yang, J.; Ma, T.; Yu, H.; Yin, M.; Qiao, Y.; Niu, L.; Yang, F.; He, J.; Li, Z., Alternations of N-glycans recognized by Phaseolus vulgaris leucoagglutinin in the saliva of patients with breast cancer. Neoplasma 2021, 68 (5), 994-1004.
12. Lee, S. B.; Bose, S.; Ahn, S. H.; Son, B. H.; Ko, B. S.; Kim, H. J.; Chung, I. Y.; Kim, J.; Lee, W.; Ko, M. S.; Lee, K.; Chang, S.; Park, H. S.; Lee, J. W.; Kim, D. C., Breast cancer diagnosis by analysis of serum N-glycans using MALDI-TOF mass spectroscopy. PLoS One 2020, 15 (4), e0231004.
13. Saldova, R.; Haakensen, V. D.; Rodland, E.; Walsh, I.; Stockmann, H.; Engebraaten, O.; Borresen-Dale, A. L.; Rudd, P. M., Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up. Mol Oncol 2017, 11 (10), 1361-1379.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-321-0
- ISBN (Online)
- 978-1-83558-322-7
- Published Date
- 06 March 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/32/20240804
- Copyright
- 06 March 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited